HIV 1 News and Research

RSS

Novel SARS-CoV-2 mutations reported in chronic HIV patients

A new study describes the emergence of new SARS-CoV-2 variants in three immunocompromised patients.

23 Jan 2022

South African study confirms SARS-CoV-2 Omicron less severe than Delta even for unvaccinated

Researchers compare the outcomes of the fourth and previous waves of the COVID-19 pandemic in South Africa.

17 Jan 2022

Topical antiseptic Acriflavine inhibits SARS-CoV-2 and other betacoronaviruses

A new study, published in the journal Cell Chemical Biology, has reported the discovery of acriflavine (ACF), an effective inhibitor of SARS-CoV-2. This drug is a mixture of trypaflavines (3,6-diamino-10-methylacridinium chloride and 3,6-diamino-3-methylacridinium chloride) and proflavine (3,6-diaminoacridine).

16 Jan 2022

Similarities and dissimilarities in immune responses and metabolism in SARS-CoV-2 and HIV-1 infections

A new study, posted to the bioRxiv* preprint server, has developed a single-cell atlas that presents the shared and distinct immune responses and metabolism following SARS-CoV-2 and HIV-1 infections.

13 Jan 2022

FAU receives $1.3 million NIH grant for automated HIV self-testing assay

As of 2020, there were 37.7 million people globally living with HIV and 680,000 people died from AIDS-related illnesses last year. Since the start of the epidemic, more than 36.3 million people have died from AIDS-related illnesses.

13 Jan 2022

Hemp compounds show ability to prevent the entry of SARS-CoV-2 into cells

Hemp compounds identified by Oregon State University research via a chemical screening technique invented at OSU show the ability to prevent the virus that causes COVID-19 from entering human cells.

11 Jan 2022

SARS-CoV-2 shown to spread through cell-to-cell transmission

A new study investigated SARS-CoV-2 cell-to-cell transmission in the context of cell-free infection and compared it to SARS-CoV.

10 Jan 2022

Exploring the plasma neutralization properties of the Omicron variant of SARS-CoV-2

A new study determines the ability of individuals with varying exposure to SARS-CoV-2 infection and vaccination, to neutralize SARS- CoV-2 pseudotypes.

16 Dec 2021

Investigational mRNA-based HIV vaccine shows promise in mice and non-human primates

An experimental HIV vaccine based on mRNA—the same platform technology used in two highly effective COVID-19 vaccines—shows promise in mice and non-human primates, according to scientists at the National Institute of Allergy and Infectious Diseases, part of the National Institutes of Health.

9 Dec 2021

WHO recommends the use of first long-acting option to protect women from HIV

The first long-acting option to protect women from HIV, proven to reduce women's HIV risk, has been recommended for use by the World Health Organization.

1 Dec 2021

Novel technique solves structure of the HIV capsid alone and in complex with host factors

A new technique using electron tomography and subtomogram averaging at Diamond's electron Bio-Imaging Centre (eBIC), has solved the structure of the HIV capsid alone and in complex with host factors.

21 Nov 2021

First long-acting injectable HIV treatment appraised and approved by NICE

ViiV Healthcare, the global specialist HIV company majority owned by GlaxoSmithKline plc, with Pfizer Inc. and Shionogi Limited as shareholders, is pleased to announce that eligible people living with Human Immunodeficiency Virus (HIV) in England and Wales will soon have routine access to Vocabria (cabotegravir long-acting injection) developed by ViiV Healthcare in combination with Rekambys (rilpivirine long-acting injection), developed by Janssen Sciences Ireland UC (Janssen), one of the Janssen Pharmaceutical Companies of Johnson & Johnson.

19 Nov 2021

Viral biomolecular condensation

A review published in PLOS Pathogens deconstructs virus condensation and provides a biochemical background for LLPS.

19 Nov 2021

LSHTM expert comments on NICE approval of first long-acting injectable HIV treatment

NHS watch-dog, the National Institute for Health and Care Excellence (NICE), has published guidance recommending the use of the first long-acting injectable treatment for HIV-1.

18 Nov 2021

Rapid antibody response induced by mRNA COVID vaccines in mice

A new study posted in the bioRxiv* preprint server used mouse models to investigate how mRNA vaccines elicit a rapid antibody response. Their findings show two different mRNA vaccines successfully boost antibody levels — IL-5, IL-6, and MCP-1 —5 days after administration.

7 Nov 2021

Oral SARS-CoV-2 Mpro inhibitor for therapeutic use

A new study describes a new small molecule compound that has shown impressive safety, tolerability, and bioavailability against SARS-CoV-2.

7 Nov 2021

Microtubule regulatory protein inhibits early HIV-1 infection, study finds

Northwestern Medicine investigators have discovered that a microtubule regulatory protein inhibits early HIV type 1 (HIV-1) infection, according to findings published in Proceedings of the National Academy of Sciences.

1 Nov 2021

Structural and molecular contributions to understanding antibody recognition of pathogenic viruses

A new review discusses how molecular and structural biology have contributed to our understanding of antibody recognition of HIV-1, SARS-CoV-2, and Zika.

1 Nov 2021

Panel of broadly neutralizing SARS-CoV-2 nanobodies for immune assay application

In this study, a team of researchers from Japanese institutions provide a panel of broadly neutralizing nanobodies that detect four VOCs.

28 Oct 2021

New class of CXCR4 antagonists could prevent airway inflammation and atopic dermatitis

Aberrant CXCR4/CXCL12 signaling is involved in many pathophysiological processes such as cancer and inflammatory diseases. A natural fragment of serum albumin, named EPI-X4, has previously been identified as endogenous peptide antagonist andinverse agonistof CXCR4 and is a promising compound for the development of improved analogues for the therapy of CXCR4-associated diseases.

18 Oct 2021